Author Archives: admin


Stem Cell Clinic > Articles by: admin

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)

By Global News Feed

GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,274,830. The issued patent gives the Company protection for its method of delivering gaseous nitric oxide (gNO) to a patient that has a condition associated with non-tuberculous mycobacteria (NTM) lung infection.

Read the rest here:
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

By Global News Feed

Lille, France; Cambridge, MA; Zurich, Switzerland; April 24, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2024. A summary of the consolidated financial statements is included below.

Read more here:
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

Seer to Report First Quarter 2025 Financial Results on May 13, 2025

By Global News Feed

REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Read this article:
Seer to Report First Quarter 2025 Financial Results on May 13, 2025

Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

By Global News Feed

IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update.

Go here to read the rest:
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

By Global News Feed

VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company’s management and scientific teams will present at the following investor and scientific conferences in April and May:

Read the rest here:
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission

By Global News Feed

Basel, 25 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).1 The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus by 32%.1 For the key secondary endpoint of influenza virus transmission resulting in symptoms, Xofluza showed a clinically meaningful reduction although statistical significance was not reached. Xofluza was well tolerated, with no new safety signals identified.1

Original post:
New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission

→←